(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 7.46%
1.26% $ 53.76
@ $53.41
Emitido: 3 may 2024 @ 14:11
Retorno: 0.66%
Señal anterior: may 3 - 10:32
Señal anterior:
Retorno: 0.96 %
Live Chart Being Loaded With Signals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally...
Stats | |
---|---|
Volumen de hoy | 1.25M |
Volumen promedio | 1.89M |
Capitalización de mercado | 12.07B |
EPS | $0 ( 2024-02-13 ) |
Próxima fecha de ganancias | ( $0.870 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.29 |
ATR14 | $1.140 (2.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Clancy Paul J | Buy | 403 | Common Stock |
2024-03-28 | Harrigan Edmund | Buy | 413 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-25 | Trotta Matteo | Buy | 21 868 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
79.28 |
Last 98 transactions |
Buy: 1 089 090 | Sell: 137 626 |
Volumen Correlación
Incyte Corp Correlación
10 Correlaciones Más Positivas | |
---|---|
NEOG | 0.941 |
DCFC | 0.922 |
JFU | 0.921 |
LSXMA | 0.92 |
GOEV | 0.92 |
LSXMK | 0.92 |
TTMI | 0.918 |
NDRA | 0.915 |
BIRD | 0.914 |
RNW | 0.913 |
10 Correlaciones Más Negativas | |
---|---|
APOP | -0.914 |
CMLF | -0.907 |
TYHT | -0.902 |
BOCN | -0.896 |
CPTA | -0.894 |
FTGC | -0.893 |
ICON | -0.893 |
EBSB | -0.892 |
BCOR | -0.891 |
AMTBB | -0.888 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Incyte Corp Correlación - Moneda/Commodity
Incyte Corp Finanzas
Annual | 2023 |
Ingresos: | $3.70B |
Beneficio Bruto: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2023 |
Ingresos: | $3.70B |
Beneficio Bruto: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2022 |
Ingresos: | $3.39B |
Beneficio Bruto: | $3.19B (93.90 %) |
EPS: | $1.530 |
FY | 2021 |
Ingresos: | $2.99B |
Beneficio Bruto: | $2.84B (94.94 %) |
EPS: | $4.30 |
Financial Reports:
No articles found.
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico